Mind Medicine Inc’s filing revealed that its Chief Legal Officer Sullivan Mark unloaded Company’s shares for reported $78139.0 on Jun 25 ’25. In the deal valued at $6.80 per share,11,491 shares were sold. As a result of this transaction, Sullivan Mark now holds 305,130 shares worth roughly $3.05 million.
Then, Karlin Daniel sold 7,848 shares, generating $53,366 in total proceeds. Upon selling the shares at $6.80, the Chief Medical Officer now owns 438,329 shares.
Before that, Barrow Robert sold 26,491 shares. Mind Medicine Inc shares valued at $180,139 were divested by the Chief Executive Officer at a price of $6.80 per share. As a result of the transaction, Barrow Robert now holds 830,065 shares, worth roughly $8.3 million.
A number of analysts have revised their coverage, including Evercore ISI’s analysts, who began to cover the stock in late January with a ‘”an Outperform”‘ rating. Chardan Capital Markets began covering MNMD with “Buy” recommendation on December 20, 2024.
Price Performance Review of MNMD
On Monday, Mind Medicine Inc [NASDAQ:MNMD] saw its stock jump 1.52% to $10.0. Over the last five days, the stock has gained 6.84%. Mind Medicine Inc shares have risen nearly 36.80% since the year began. Nevertheless, the stocks have risen 43.68% over the past one year. While a 52-week high of $10.44 was reached on 02/14/25, a 52-week low of $4.70 was recorded on 04/09/25.
Levels Of Support And Resistance For MNMD Stock
The 24-hour chart illustrates a support level at 9.76, which if violated will result in even more drops to 9.51. On the upside, there is a resistance level at 10.27. A further resistance level may holdings at 10.53.
How much short interest is there in Mind Medicine Inc?
A steep rise in short interest was recorded in Mind Medicine Inc stocks on 2025-07-15, growing by 0.16 million shares to a total of 11.22 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 11.07 million shares. There was a rise of 1.41%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on July 24, 2024 when ROTH MKM began covering the stock and recommended ‘”a Buy”‘ rating along with a $36 price target.
